Watson Pharmaceuticals Inc. recently announced that the US Food and Drug Administration has approved the company's abbreviated new drug application for a generic version of Roche Holding Ltd.'s ...

Osteoporosis drug Boniva, a GlaxoSmithKline (NYSE:GSK) and Roche (OTC:RHHBY) product, will soon face its first generic competitors. Mylan (NASDAQ:MYL), Apotex and Orchid Healthcare all received U ...

Watson Pharma plans to begin shipping its generic version (150 mg) in the second quarter of 2012. Roche and Watson Pharma are currently fighting a patent infringement lawsuit for the ANDA of ...

WASHINGTON (Reuters) – Patients who want an injectable form of Roche Holding AG’s bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not ...

Watson Pharma plans to begin shipping its generic version (150 mg) in the second quarter of 2012. Roche and Watson Pharma are currently fighting a patent infringement lawsuit for the ANDA of Boniva.

Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately forecast demand ...

The first generic versions of Roche's bone-strengthening drug Boniva have been approved by the U.S. Food and Drug Administration. Boniva, known generically as ibandronate, is taken once a month to ...

Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately forecast demand ...

Osteoporosis drug Boniva, a GlaxoSmithKline (NYSE:GSK) and Roche (OTC:RHHBY) product, will soon face its first generic competitors.Mylan (NASDAQ:MYL), Apotex and Orchid Healthcare all received U.S ...

Unlike Boniva tablets, which people take once a month, Boniva injections are given once every three months. The U.S. Food and Drug Administration announced the shortage of Boniva vials on its ...

Apotex Inc. agreed to delay selling a generic version of the osteoporosis drug Boniva until a judge rules on the validity of a Roche Holding AG patent on the medicine that expires in March 2012.